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Abstract The term ‘‘acute transverse myelitis (ATM)’’
comprises various non-traumatic disorders that eventually
can be associated with a focal myelopathy. Patients char-
acteristically present with an acutely occurring paraparesis/
plegia and require a comprehensive and timely diagnostic
work up for the initiation of an appropriate treatment. We
present a case of a 36-year-old female patient with a rare
genetic disorder (ANE1: Acute Necrotizing Encephalopa-
thy due to a RANBP2 mutation) who presented with an
acute quadriplegia. Following an acute pulmonal infection,
she rapidly (\24 h) developed a severe quadriplegia (total
motor score 38) with some facial sensory symptoms (per-
ioral hypoesthesia). Magnetic resonance imaging (MRI)
revealed a combination of longitudinal extensive transverse
myelitis and symmetrical thalamic lesions. A work-up for
infectious and systemic diseases was negative; specifically,
no findings related to multiple sclerosis, neuromyelitis
optica or vascular disorders. After empirical high dose
steroid treatment and rehabilitation therapy, the patient
gained almost normal gait and upper limb function. She
was found to carry an autosomal-dominant missense
mutation in the RANBP2 gene predisposing for ANE.
Gene segregation was confirmed in other family members
that had been affected by other episodes of acute steroid-
responsive encephalopathies. We propose that a redefined
diagnostic workup of ATM might include ANE1, as the
frequency of this rare disorder might be underestimated.
Keywords Acute necrotizing encephalopathy  Spinal
cord injury  Transverse myelopathy  Transverse myelitis 
Acute disseminating encephalomyelitis
Introduction
Acute transverse myelitis (ATM) is a rare cause of non-
traumatic spinal cord injury (ntSCI) comprising a hetero-
geneous group of immune-mediated diseases. The typical
clinical presentation is a non-traumatic paraplegia with an
acute (frequently within hours) onset. The first documented
use of the term ‘‘acute transverse myelitis’’ was by Miller
and Ross in 1931, describing a case of acute quadriplegia
in a child following measles with complete regaining of
function on later follow-up [1]. Following this initial
report, several publications focused on the topic of trans-
verse myelitis—mainly in cases of acute post-vaccination
or parainfectious paraplegia. These publications predomi-
nantly derived from pediatric cases where ATM occurred
after viral diseases (like rubella or measles). The diagnostic
term ATM was clinically applied in a rather descriptive
manner, while in many cases the definite etiology remained
unclear.
Eventually, more refined etiological mechanisms of
ATM were introduced, based on increasing knowledge in
neuro-immunology and improvements in neuro-imaging
(i.e. magnetic resonance imaging [MRI]). These methods
are sensitive to distinguish different clinical entities (or
disorders), thus improving the diagnostic yield [2–6]. ATM
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was classified as a neurological syndrome based on
immuno-reactive pathomechanisms with a typically acute
or sub-acute onset. Today for diagnosing ATM, the proof
of a neuro-immunological pathomechanism is required by
either a positive cerebrospinal fluid (CSF) (pleozytosis or
positive immunoglobulin index), or by defined MRI sug-
gestive for central nervous system (CNS) inflammation
(MRI of the entire neuro-axis including gadolinium
administration) [5, 7, 8]. In contrast to ATM, the term
‘‘transverse myelopathy’’ is used rather broadly, referring
to non-traumatic spinal cord lesions in general [6, 8].
We present a clinical case of ATM showing longitudinal
extensive transverse myelitis, as well as thalamic involve-
ment, that was found to carry a genetic mutation that has been
recently reported to predispose to infection-triggered Acute
Necrotizing Encephalopathy (ANE1) [9]. Based on this rare
case of a genetically triggered ATM, we propose a refined
diagnostic algorithm including this hereditary disorder in
order to emphasize this potential pathomechanism in ATM.
This case report has been performed in accordance with the
ethical standards laid down in the Declaration of Helsinki; a
written informed consent of the patient was obtained.
Case report
Medical history
In January 1999, a 36-year-old woman was admitted with
an acute onset of an incomplete quadriplegia (American
Spinal Injury Association [ASIA] impairment scale C,
level C4) and a defined perioral hypoesthesia around the
mouth (dermatomes innervated by the long projecting tri-
geminal spinal roots).
The sensory-motor deficits occurred rapidly within 24 h,
3 days after the onset of unspecific infectious symptoms of
the upper respiratory tract with coughing and fever
(39.5 C). Prior to this episode, her health was unremark-
able and she had never suffered from any neurological or
other systemic disorder. Similar infectious symptoms had
occurred to her in the past, but they had rarely been
accompanied by fever.
Diagnostic workup
Clinical presentation
Glasgow coma scale (GCS) was 15/15 points; other than a
mild perioral hypoesthesia, the cranial nerves were intact.
Tendon reflexes were abolished except for biceps reflexes,
which were symmetrically weak. Babinski sign was nega-
tive and muscle tone was hypotonic. Motor level was at C5,
sensory level at C4, both at left and right side
symmetrically. Severe paresis affected all muscles of the
lower and upper limbs, inducing a total loss of her walking
ability and a severely impaired upper limb function (total
ASIA motor score 38/100). Below the level of lesion at C4,
aesthesia and algesia were incompletely impaired. There
was hypoesthesia and hypalgesia in the sacral dermatomes,
bulbocavernosus reflex was negative and there was no
voluntary sphincter contraction, or voluntary urinary
voiding. Respiratory and cardiac functions were unre-
markable, skin showed no noticeable alterations.
Laboratory workup
The initial cerebrospinal fluid (CSF) analysis showed a nor-
mal cell count (0.3/ll, leukocytes), but increased protein
levels (0.79 g/l). Oligoclonal bands (OCB) were negative and
a blood-CSF barrier disturbance was found (albumin quotient
19.7, IgG quotient 0.44) without intrathecal synthesis of
immunoglobulins. A second CSF analysis revealed a pleo-
cytosis of 19 cells per ll consisting mostly of monocytes,
while blood-CSF-barrier was still impaired.
Blood exams showed normal cell counts, erythrocytes
sedimentation rate of 3 mm/h, normal C-reactive protein
and no liver or renal dysfunction. The screening for
immunological disorders was negative (RF, ANA, ANCA,
anti-ds-DNA, SSA/SSB). Vitamin B12 was at normal level.
No specific viral or bacterial infection was found in the
blood or the CSF (cytomegalovirus, adenoviruses, Epstein-
Barr virus, varicella zoster virus, herpes simplex virus
I ? II, coxsackie virus, HIV, treponema pallidum, borre-
liosis, leptospirosis, mycobacteria, aspergillum, brucello-
sis, chlamydia, bartonellosis, campylobacter, salmonella,
legionella). The pulmonal or bronchial infection causing
the initial fever could not be specified.
NMO-(aquaporine-4)-antibodies were not for routine
diagnostics at that time (1999), and therefore were not
investigated initially. However, at follow-up analysis,
NMO-antibodies in 2012 were negative.
Neuroimaging
The MRI of the spine showed an extensive myelopathy
ranging from C2-Th1 and a second myelopathic area at the
conus medullaris that were suggestive for an extensive
inflammation (see Fig. 1). Brain MRI revealed several
symmetrical lesions of the anterior thalamus, within the
pons and the medulla oblongata (see Fig. 2). There were no
findings suggestive for vascular or tumor disorders.
Electrophysiology
Electrophysiology showed initially severe axonal lesions in
the upper limb nerves with normal nerve conduction
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Fig. 1 MRI 2 days after onset
of symptoms: extensive lesion
of the cervical spine and the
conus medullaris
Fig. 2 MRI 2 days after onset of symptoms: lesion in the thalamus, pons and medulla oblongata
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velocity and loss of F-waves. Nerve conduction studies of
the tibial nerves showed normal amplitudes, conduction
velocities and F-wave latencies. The results were atypical
for Guillain–Barre Syndrome (GBS), but indicated a severe
axonal loss due to the intramedullar lesion of the anterior
horn cells in the cervical spine. Measurements after
4 weeks showed a reduction of amplitudes (40 %) in the
tibial nerves and prolongation of F-wave latencies (60 ms).
At 5 months, amplitudes of the upper limb nerves recov-
ered slightly (max 2.6 mV), whereas amplitudes of the
lower limb nerves remained normal (9 mV/17 mV).
F-wave latencies recovered to slight impaired values in the
upper limbs (28–30 ms ulnar nerves, 30–35 ms median
nerves) and to normal values in the lower limbs (54–55 ms
tibial nerves).
Treatment and course
Steroid therapy (Dexamethasone orally 4 9 4 mg/day for
8 days and consecutive reduction) was empirically initiated.
Within 1 month, the signal-alterations on the MRI of the
central nervous system were reduced—small lasting altera-
tions were found in the thalamus, the cervical spine and in
the conus medullaris—matching the clinical improvements.
In the following, the patient regained sensibility and
reflexes, motor deficits improved slowly and she regained
walking-ability with crutches and independency from assis-
tance within 5 months. Bladder and bowel deficiency restored
to a fully normal function. After discharge, she improved
further to an almost normal gait (no walking aids required,
walking distance unlimited but slightly reduced speed). Fol-
low-up MRI showed persistent minor myelopathy in the
cervical spinal cord and symmetric residual T2-hyperintense
lesions in the thalamus (see Fig. 3). No new T2-hyperintense
lesions occurred. Since 1999, the patient did not experience
any additional episode of an acute CNS impairment.
Family history
The patient presented above is born in Switzerland as one
of seven children (see pedigree, Fig. 4). Her mother derives
from a large family with a total of eleven siblings. One of
her aunts died at young age from an unknown cause. The
patient’s second cousin who was born in 2000 suffered
from recurrent episodes of ANE, and was as an index
patient tested and found positive for a missense mutation
on the RANBP2 gene on chromosome 2q12.1–2q13 in
2007 [9]. The father of this child, the patient’s first cousin,
was tested positive for the mutation as well, without any
prior or later history of infection-triggered encephalopathy.
Another first cousin born in 1958 is reported to have suf-
fered from acute cerebral disorder (non-traumatic coma in
childhood) with consecutive residual mental retardation.
This cousin’s caretaker refused the genetic testing.
The present patient was found to carry the missense
mutation associated with ANE1 as well [9].
Discussion
The understanding of ATM has continuously improved
over the last decades, and comprises various mainly
immune-mediated myelopathies. Accordingly, definitions
and diagnostic criteria will have to be adjusted as further
insights in pathology and course of disorders are revealed.
Acute transverse myelitis: definitions and epidemiology
ATM is clinically recognized by an acute to subacute
development of a paraparesis or paraplegia with a maxi-
mum of deficits within 4 h up to 21 days [6]. While signs
of CNS or systemic inflammation (CSF pleocytosis, IgG-
elevation, MRI gadolinium enhancement) [5, 6, 8, 10] are
Fig. 3 MRI 2012: residual lesions in thalamus (arrows) and cervical spinal cord
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key findings, other causes (e.g. vascular disorders, tumors,
degeneration) need to be excluded. Severity of symptoms,
extent of inflammation, time and slope of symptoms may
hint towards the etiology or potential differential-diagnosis
[5, 8, 11]. After repeated exclusion of up-to-date known
causes for ATM, idiopathic ATM might be diagnosed
according to the Transverse Myelitis Consortium Group
(TMCG). [5].
Due to continuous changes in criteria and definition of
ATM, epidemiological studies are hardly comparable. An
early study targeting the incidence of ATM in adults was
done from 1955 to 1975 in Israel by Berman et al. [3],
stating an annual incidence of 1.34 per million per year.
Estimates in other studies even range to 31 per million per
year, depending on definition and inclusion criteria (e.g.
ATM in MS/NMO/systemic diseases (SD), definition by
ICD10) [4, 12, 13]. Although ATM can manifest at any
age, three peaks are described at the age of 0–5, 10–19 and
30–39 years [3, 4, 14, 15].
The differential diagnosis in ATM
The challenge in the diagnosis of ATM lies in a compre-
hensive and timely diagnostic workup (Fig. 5) for as in the
majority of disorders, advising appropriate treatments and
early interventions are assumed to be important for
improved outcomes.
Neuro-immunological disorders (i.e. multiple sclerosis
[MS], neuromyelitis optica [NMO]) represent the most
frequent cause of ATM, as has been shown in a large
multicentre ATM-cohort study (seven centers, spinal cord
infarct excluded; n = 234: MS 13.3 % and NMO 20.9 %
resp.) [16]. The McDonald criteria define four areas within
the CNS that are most commonly affected by MS: peri-
ventricular, infratentorial and juxtacortical region and the
spinal cord [17]. In general, ATM as a symptom of clini-
cally definite MS occurs rather rare (in about 0–11 % of
adult MS patients [18]). The conversion rate of isolated
complete ATM into clinically definite MS is estimated at
less than 2 % per 5 years [19]. Risk factors for the later
development of MS are the extent of inflammation (rather
partial), positive OCB or abnormal brain MRI (if not yet
fulfilling MS criteria) [11, 20, 21]. Partial ATM is, in
contrast to complete ATM, much more likely to be a
symptom of MS [22]: the conversion rate into clinical
definite MS ranges between 20–30 % over 5 years [19],
while Cordonnier et al. [21] even stated a conversion rate
of 57.7 %. NMO (also called Devic syndrome), rather
recently, is considered a separate entity from MS. NMO is
defined by the combination of longitudinal extensive
transverse myelitis (LETM) and optical neuritis [23]. Since
aquaporin-4-Ab were found to be associated with this
disease, the distinction from MS is now widely accepted.
OCB are typically not found and the myelitis is required to
involve the height of three vertebral segments. Patients
with isolated LETM are at high risk to develop NMO or
relapsing LETM if NMO-Ab are positive [24, 25].
Systemic immunologically mediated diseases have
been shown to be the second largest subgroup of dis-
eases causing ATM (25.1 %, n = 234) [16]. Sjo¨gren’s
syndrome was most often diagnosed (28 cases, 12 %)
followed by sarcoidosis (17 cases, 7.2 %) followed by
Fig. 4 Pedigree
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SLE/antiphospholipide syndrome (14 cases, 6 %) [16]. In a
Japanese or Turkish descent, Behc¸et’s disease might also
cause ATM [26]. Sjo¨gren’s syndrome, sarcoidosis, SLE
and Behc¸et’s disease need to be screened for by serologic
markers (Anti-SSA/B, ACE, ANA ? ds-DNA/anti-phos-
pholipide-Ab, HLA-B51, respectively) complementing
imaging and clinical history. Several clinical symptoms
might hint to the diagnoses (e.g. sicca-syndrom, uveitis,
other organ involvement (kidney, heart, lungs), mucosal
ulcers, respectively) [8, 27]. Funicular myelosis or copper-
deficiency related myelopathies usually present chroni-
cally, MRI reveals typically longitudinal lesions of the
dorsal column, and CSF analysis might show signs of
blood–brain-barrier breakdown [28, 29].
Infectious and parainfectious disorders together are
reported to cause ATM in 21.4 % of cases [16]. Viral CNS
infections commonly present as acute meningoencephalitis,
and if the spinal cord is involved, a partial transverse
myelitis is more likely [30]. True ATM caused by viral
infections that are actually identified by CSF analysis are
rarely reported (Coxsackie A/B Virus, Enterovirus, hepa-
titis A/C virus, varicella zoster virus, Epstein-Barr virus
and cytomegalovirus [30–35]). Reports of ATM associated
with other viral diseases (influenza, measles, rubella, polio,
adenovirus) are rather heterogenic, and might be classified
as parainfectious ATM [18, 36]. Bacterial or mycobacterial
ATM are also rarely reported: mycoplasma pneumonia
(37 cases), schistosomiasis (one case) [36], brucellosis
Fig. 5 Proposed diagnostic
scheme. ATM acute transverse
myelitis, ANE acute necrotizing
encephalopathy, AP-4-Ab
aquaporine-4-antibodies, cMRI
cranial magnetic resonance
imaging, CSF cerebrospinal
fluid, DOT/S dissemination of
time/space, NMO neuromyelitis
optica, OCB oligoclonal bands.
*Mycoplasma, treponema
pallidum, borreliosis,
mycobacterium tuberculosis,
chlamydia, brucellosis,
cocksackievirus, HTLV; VZV;
HIV; HHV1 ? 2, CMV, EBV,
adenovirus, HCV, HAV.
**ANA, ANCA; ds-DNA,
antiphospholipide-Ab, anti-
Ro/SSA, ACE, HLA-B51
depending on clinical symptoms.
Thickness and shape of lines
indicates the relative frequency
of disorders diagnosed in ATM:
Solid lines[20 %, spaced
dashed lines 10–20 %, dashed
lines 5–10 %, dotted lines\5 %
1550 J Neurol (2013) 260:1545–1553
123
infections (20 cases) [37, 38], two cases of chlamydia
psittaci [39] and four cases of documented Lyme neurob-
orelliosis [40]. Although neurosyphilis presents mainly as
chronic myelopathy, there are two reported cases of ATM
[41]. Comparably tuberculosis shows a rather chronic
progression, but in rare cases neurological presentation can
manifest as ATM (three cases) [42]. A larger percentage of
ATM is assumed to be parainfectious and it is defined by a
prior history of a mostly viral infection. Vaccine-associated
ATM contributes to this subgroup although post-vaccina-
tion ATM is rare [18].
Idiopathic ATM is considered a diagnosis by exclusion
and exact definitions remain unclear. The TMCG was the
first to assess specific criteria and an exclusion of prior
infections or vaccinations is not uniformly required [5].
Accordingly, a recent retrospective analysis in children
applying the TMCG criteria did not differentiate parain-
fectious from idiopathic ATM [43], while De Seze et al.
and Borchert et al. excluded parainfectious ATM [16, 18].
An Intergroup correlation addressing a group difference
between idiopathic and parainfectious ATM is not pub-
lished. The outcome of idiopathic ATM according to
TMCG criteria was retrospectively investigated by de Seze
et al. [16]: The subgroup of idiopathic ATM was shown to
be heterogeneous in terms of clinical presentations, extent
of spinal lesion and outcome, and criteria for outcome
prediction could not be identified.
A comparable parainfectious pathophysiological mech-
anism is considered in acute disseminated encephalomy-
elitis (ADEM), as mentioned by Al Deeb et al. in 1997
[44]. The diagnosis of ADEM calls for a monophasic
inflammatory demyelinating disease that can, but does not
need to, be associated with acute viral infection or vacci-
nation [45]. Typical clinical presentation is acute, multi-
focal and poly-symptomatic (meningomyeloencephalitis),
and CNS involvement can include inflammation of the
spinal cord [45]. Neuroimaging reveals non-MS typical
lesions (e.g. deep grey matter involvement, sparing of
periventricular white matter), but a reliable distinction to
MS and NMO can be difficult [46].
Intramedullary tumors should be excluded by spinal
MRI, although in some cases associated edema and gado-
linium enhancements might be challenging [47]. Paraneo-
plastic disorders might cause subacute myelopathy, e.g. the
small cell lung carcinoma and related autoimmunities [48]
or neurochemical toxicity [47].
Transverse myelitis and ANE1
The acute necrotizing encephalopathy (ANE) is an acute
and severe parainfectious CNS disease rarely diagnosed in
adult neurology. It is known as a disease of childhood, first
described in 1965 [49] and later on reported in mostly
Japanese children in the 90s [50]. By now, it is known that
this form of acute encephalopathy in children occurs
worldwide [51, 52]. Since 2000, few cases on ANE in
adults have been reported [53–57].
ANE is defined by a rapid progressive encephalopathy
after a common viral infection as influenza or parainfluenza
[50]. The criteria of ANE require exclusion of direct viral
or bacterial infection of the CNS [58]. The MRI shows
multiple lesions of the CNS: typically symmetrical lesions
of the thalami, pons and brain stem [59]. Elevated liver
enzymes contribute to the diagnosis [59]. The pathophys-
iological mechanisms are not known. It is supposed that the
encephalopathy and the neuronal damage and necrosis is
mediated by the specific effect of an excessive cytokine
release in the CSF [60]. Some patients with ANE showed a
dramatic response to early high–dose steroids [61].
While ANE usually occurs sporadically, few cases of
recurrent and/or familial episodes suggesting an inherited
disposition have been reported [62]. In 2009, a genetic
disorder with incomplete autosomal-dominant trait was
reported: a missense mutation in the gene coding for
the nuclear pore Ran Binding Protein 2 (RANBP2,
OMIM*601181) on chromosome 2q was found to transmit
a predisposition for familial ANE (=ANE1) in European,
Asian and African families [9, 63]. Among the familial
cases, the formation of CNS lesions was found to be more
disseminated than originally described for ANE, including
spinal cord lesions. In addition, not only children but also
adolescents and one adult (described herein) were observed
to be affected [9]. No patient with ANE1 showed elevated
liver enzymes, in contrast to ANE. Importantly, the mis-
sense mutation leading to ANE1 was shown to be distin-
guished from MS, since there was no such mutation found
within a representative collective of MS-patients [9].
ANE1, according to Neilson et al. and Bergamino et al.,
should be considered if criteria for ANE and any of the
following are met: (I) familial history of neurological
symptoms, might be parainfectious, (II) recurrent enceph-
alopathy following fever, (III) additional MRI changes in
one of the following: medial temporal lobes, insular cor-
tices, claustrum, external capsule, amygdale, hippocampi,
mammillary bodies, and spinal cord [64].
The missense mutation in the RANBP2-gene and its
actual function within the pathological mechanisms of
ANE1 are not yet entirely understood. It transmits an
increased vulnerability for developing an episode of ANE1
triggered by a variety of mostly viral infections [9]. Many
different molecular possibilities are discussed [9], but one
trait that is already known for other diseases offers a plau-
sible explanation: The protein is known to play a role in the
energy metabolism of neuronal cells [65, 66]. Hence, one
theory is that a malfunction of the RANBP2 nuclear pore
leads to an energy breakdown when the cell mechanisms are
J Neurol (2013) 260:1545–1553 1551
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challenged by an acute infection [9]. Similar mechanisms
are already assumed for other infection mediated encepha-
lopathy-syndromes such as Reye’s (like) syndrome (Mito-
chondriopathy caused by different enzymatic deficiencies
[67]), Wernicke Encephalopathy (hypovitaminosis induc-
ing lack of glucose catabolism and deficit in mitochondrial
metabolism [68]) or—genetically determined—Leigh
Syndrome (mitochondrial disease [69]).
Summary and conclusion
Our patient represents a very rare case of an ANE1-asso-
ciated ATM that presented with an acute quadriplegia. The
patient met the criteria for ANE1 with typical radiological
features, positive family history and a proven missense
mutation in the RANBP2-gene. The sudden onset after an
infection (3 days) and symmetrical T2-hyperintense cere-
bral (thalamus and pons) lesions are typical findings in
ANE1, although involvement of the spinal cord has been
reported in only three cases [9]. The favorable outcome
might be due to the steroid treatment, as steroid respon-
siveness is known for ANE [64]. This case emphasizes the
diagnostic challenges in ATM, and a diagnostic algorithm
is proposed to guide a timely and comprehensive work up
for introducing appropriate treatments (Fig. 5).
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